These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
(State or other jurisdiction of
|
|
(IRS Employer
|
incorporation or organization)
|
|
Identification No.)
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
|
|
(Nasdaq Global Select Market)
|
|
☒
|
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☐
|
|
Smaller reporting company
|
|
Emerging growth company
|
|
|
|
|
*
|
For purposes of this calculation, all outstanding shares of common stock have been considered held by non-affiliates other than the 832,991 shares beneficially owned by directors and executive officers. In making such calculation, the Registrant does not determine the affiliate or non-affiliate status of any shares for any other purpose.
|
Form 10-K
|
|
|
Item No.
|
|
Name of Item
|
|
|
|
|
|
|
|
||
|
||
|
||
|
||
|
||
|
||
|
|
|
|
|
|
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
|
|
|
|
|
|
||
|
||
|
||
|
||
|
||
|
|
|
|
|
|
|
||
|
•
|
Potential failure of third parties on which the Company relies, including its suppliers, commercial banks, and other external business partners to meet their obligations to the Company, or significant disruptions in their ability to do so, which may be caused by their own financial or operational difficulties, or by travel restrictions and border closures;
|
•
|
Negative impact on the Company’s workforce. The spread of COVID-19, for example, has caused the Company to modify its business practices (including employee travel and work locations, cancellation of physical participation in meetings, events and conferences and a furlough of the majority of store associates and a portion of corporate associates), and the Company may take further actions as may be required by government authorities or that the Company determines are in the best interests of its employees;
|
•
|
Significant changes in the political conditions in markets in which the Company distributes its products have occurred and are expected to continue at least during the pendency of the pandemic, including quarantines, governmental or regulatory actions, closures or other restrictions that limit or close its operating facilities, restrict its employees’ ability to travel or perform necessary business functions, or otherwise restrict the operations and purchasing behaviors of its business partners, suppliers or customers;
|
•
|
Potential impact on the Company’s ability to meet its obligations to business partners, including under its unsecured revolving credit facility agreement, which contains a maximum leverage ratio, customary representations, warranties and affirmative covenants, and its current lease obligations. The Company is renegotiating payment terms for goods, services and rent. Similar to other retailers, the Company has also withheld portions of and/or delayed payments to certain of its business
|
•
|
Significant reductions in demand or significant volatility in demand for the Company’s products, which has been and may continue to be caused by, among other things,
the temporary inability of consumers to shop at its stores or buy its products due to illness, quarantine or other travel restrictions, unemployment or other financial hardship, and shifts in demand away from one or more of the Company’s more discretionary or higher priced products to lower priced products;
and
|
•
|
Disruptions in the financial markets may materially adversely affect the availability and cost of credit to the Company.
|
STORE LOCATIONS
|
|
|
|
|
||
|
|
|
|
|
||
Alabama
|
23
|
|
|
New York
|
98
|
|
Alaska
|
1
|
|
|
North Carolina
|
44
|
|
Arizona
|
38
|
|
|
North Dakota
|
3
|
|
Arkansas
|
8
|
|
|
Ohio
|
45
|
|
California
|
174
|
|
|
Oklahoma
|
11
|
|
Colorado
|
34
|
|
|
Oregon
|
17
|
|
Connecticut
|
25
|
|
|
Pennsylvania
|
39
|
|
Delaware
|
6
|
|
|
Rhode Island
|
5
|
|
Florida
|
96
|
|
|
South Carolina
|
23
|
|
Georgia
|
39
|
|
|
South Dakota
|
3
|
|
Hawaii
|
1
|
|
|
Tennessee
|
26
|
|
Idaho
|
9
|
|
|
Texas
|
115
|
|
Illinois
|
47
|
|
|
Utah
|
14
|
|
Indiana
|
22
|
|
|
Vermont
|
3
|
|
Iowa
|
9
|
|
|
Virginia
|
47
|
|
Kansas
|
12
|
|
|
Washington
|
36
|
|
Kentucky
|
12
|
|
|
West Virginia
|
3
|
|
Louisiana
|
20
|
|
|
Wisconsin
|
14
|
|
Maine
|
8
|
|
|
Wyoming
|
2
|
|
Maryland
|
22
|
|
|
District of Columbia
|
3
|
|
Massachusetts
|
44
|
|
|
Puerto Rico
|
3
|
|
Michigan
|
42
|
|
|
Alberta, Canada
|
15
|
|
Minnesota
|
14
|
|
|
British Columbia, Canada
|
11
|
|
Mississippi
|
7
|
|
|
Manitoba, Canada
|
2
|
|
Missouri
|
22
|
|
|
New Brunswick, Canada
|
2
|
|
Montana
|
9
|
|
|
Newfoundland and Labrador, Canada
|
1
|
|
Nebraska
|
8
|
|
|
Nova Scotia, Canada
|
2
|
|
Nevada
|
15
|
|
|
Ontario, Canada
|
27
|
|
New Hampshire
|
15
|
|
|
Prince Edward Island, Canada
|
1
|
|
New Jersey
|
92
|
|
|
Saskatchewan, Canada
|
2
|
|
New Mexico
|
9
|
|
|
Total
|
1,500
|
|
Period
|
Total Number of
Shares Purchased (1)
|
Average Price
Paid per Share (2)
|
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans
or Programs (1)
|
Approximate Dollar
Value of Shares
that May Yet Be
Purchased Under
the Plans or
Programs (1) (2)
|
||||||
December 1, 2019 - December 28, 2019
|
30,900
|
|
$
|
15.45
|
|
30,900
|
|
$
|
1,236,668,444
|
|
December 29, 2019 - January 25, 2020
|
2,600
|
|
$
|
12.80
|
|
2,600
|
|
$
|
1,236,635,172
|
|
January 26, 2020 - February 29, 2020
|
5,400
|
|
$
|
12.34
|
|
5,400
|
|
$
|
1,236,568,539
|
|
Total
|
38,900
|
|
$
|
14.84
|
|
38,900
|
|
$
|
1,236,568,539
|
|
Consolidated Selected Financial Data
|
Fiscal Year Ended (1)
|
||||||||||||||
(in thousands, except per share
and selected operating data)
|
February 29,
2020
|
March 2,
2019
|
March 3,
2018 (2) |
February 25,
2017 (3) |
February 27,
2016 |
||||||||||
|
|
|
|
|
|
||||||||||
Statement of Operations Data:
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
||||||||||
Net sales
|
$
|
11,158,580
|
|
$
|
12,028,797
|
|
$
|
12,349,301
|
|
$
|
12,215,757
|
|
$
|
12,103,887
|
|
|
|
|
|
|
|
||||||||||
Gross profit
|
3,541,660
|
|
4,103,980
|
|
4,443,015
|
|
4,576,350
|
|
4,620,310
|
|
|||||
|
|
|
|
|
|
||||||||||
Operating (loss) profit (8)
|
(700,064
|
)
|
(87,135
|
)
|
761,321
|
|
1,135,210
|
|
1,414,903
|
|
|||||
|
|
|
|
|
|
||||||||||
Net (loss) earnings
|
(613,816
|
)
|
(137,224
|
)
|
424,858
|
|
685,108
|
|
841,489
|
|
|||||
|
|
|
|
|
|
||||||||||
Net (loss) earnings per share - Diluted
|
$
|
(4.94
|
)
|
$
|
(1.02
|
)
|
$
|
3.04
|
|
$
|
4.58
|
|
$
|
5.10
|
|
|
|
|
|
|
|
||||||||||
Dividends declared per share (6)
|
$
|
0.68
|
|
$
|
0.64
|
|
$
|
0.60
|
|
$
|
0.50
|
|
$
|
—
|
|
|
|
|
|
|
|
||||||||||
Selected Operating Data:
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
||||||||||
Number of stores open (at period end)
|
1,500
|
|
1,533
|
|
1,552
|
|
1,546
|
|
1,530
|
|
|||||
|
|
|
|
|
|
||||||||||
Total square feet
|
|
|
|
|
|
||||||||||
of store space (at period end)
|
42,262,500
|
|
43,132,000
|
|
43,681,000
|
|
43,619,000
|
|
43,274,000
|
|
|||||
|
|
|
|
|
|
||||||||||
Percentage (decrease) increase in comparable sales (4)
|
(6.8
|
%)
|
(1.1
|
%)
|
(1.3
|
%)
|
(0.6
|
)%
|
1.0
|
%
|
|||||
|
|
|
|
|
|
||||||||||
Comparable sales (in 000's) (4)
|
$
|
10,788,631
|
|
$
|
11,604,110
|
|
$
|
11,813,092
|
|
$
|
11,701,042
|
|
$
|
11,722,973
|
|
|
|
|
|
|
|
||||||||||
Balance Sheet Data (at period end):
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
||||||||||
Working capital
|
$
|
1,359,759
|
|
$
|
1,832,340
|
|
$
|
1,805,393
|
|
$
|
1,559,400
|
|
$
|
1,757,282
|
|
|
|
|
|
|
|
||||||||||
Total assets (9)
|
7,790,515
|
|
6,570,541
|
|
7,040,806
|
|
6,822,655
|
|
6,487,677
|
|
|||||
|
|
|
|
|
|
||||||||||
Long-term operating lease liabilities (9)
|
1,818,783
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|||||
|
|
|
|
|
|
||||||||||
Long-term sale/leaseback and capital lease
|
|
|
|
|
|
||||||||||
obligations
|
102,412
|
|
103,983
|
|
105,614
|
|
107,136
|
|
109,274
|
|
|||||
|
|
|
|
|
|
||||||||||
Long-term debt (5)
|
1,488,400
|
|
1,487,934
|
|
1,492,078
|
|
1,491,603
|
|
1,491,137
|
|
|||||
|
|
|
|
|
|
||||||||||
Shareholders' equity (6) (7)
|
$
|
1,764,935
|
|
$
|
2,560,331
|
|
$
|
2,888,628
|
|
$
|
2,719,277
|
|
$
|
2,559,540
|
|
•
|
Net sales in fiscal
2019
(fifty-two weeks) decreased approximately
7.2%
to
$11.159 billion
; net sales in fiscal
2018
(fifty-two weeks) decreased approximately
2.6%
to
$12.029 billion
over net sales of
$12.349 billion
in fiscal
2017
(fifty-three weeks).
|
•
|
Comparable sales in fiscal
2019
(fifty-two weeks) decreased by approximately
6.8%
, as compared to a decrease of approximately
1.1%
for fiscal
2018
(fifty-two weeks) and a decrease of approximately
1.3%
for fiscal
2017
(fifty-three weeks). Comparable sales percentages are calculated based on an equivalent number of weeks in each annual period. For fiscal
2019
, comparable sales consummated through customer facing digital channels increased in the low-single-digit percentage range, while comparable sales consummated in-store declined in the high-single-digit percentage range from the corresponding period in the prior year. For fiscal
2018
, comparable sales consummated through customer facing digital channels continued the trend of year over year strong growth, while comparable sales consummated in-store declined in the mid-single-digit percentage range from the corresponding period in the prior year.
|
•
|
Gross profit for fiscal
2019
was
$3.542 billion
or
31.7%
of net sales, compared with
$4.104 billion
or
34.1%
of net sales for fiscal
2018
and
$4.443 billion
or
36.0%
of net sales for fiscal
2017
.
|
•
|
SG&A for fiscal
2019
were
$3.732 billion
or
33.4%
of net sales, compared with
$3.681 billion
or
30.6%
of net sales for fiscal
2018
and
$3.682 billion
or
29.8%
of net sales for fiscal
2017
.
|
•
|
Goodwill and other impairments for fiscal
2019
were
$509.2 million
or
4.6%
of net sales compared with
$509.9 million
or
4.2%
of net sales for fiscal
2018
. There were no goodwill and other impairments in fiscal
2017
.
|
•
|
Interest expense, net was
$64.8 million
,
$69.5 million
, and
$65.7 million
in fiscal
2019
,
2018
and
2017
, respectively.
|
•
|
The effective tax rate was
19.7%
,
12.4%
, and
38.9%
for fiscal years
2019
,
2018
and
2017
, respectively.
|
•
|
For the fiscal year ended
February 29, 2020
(fifty-two weeks), net loss per diluted share was
$(4.94)
(
$(613.8) million
) and included the unfavorable impact of approximately $5.40 per diluted share from goodwill and other impairments, an incremental charge for markdowns, severance costs, shareholder activity costs and a loss from a sale-leaseback transaction, including transaction costs. For the fiscal year ended
March 2, 2019
(fifty-two weeks), net earnings per diluted share was
$(1.02)
(
$(137.2) million
) and included the unfavorable impact of approximately $2.99 per diluted share from goodwill and other impairments, severance costs and a gain from the sale of a building, and for the fiscal year ended
March 3, 2018
(fifty-three weeks), net earnings per diluted share was
$3.04
(
$424.9 million
).
|
|
Fiscal Year Ended
|
|||||||||||||
|
Percentage
of Net Sales
|
|
Percentage Change
from Prior Year
|
|||||||||||
|
February 29,
2020 |
|
March 2,
2019 |
|
March 3,
2018 |
|
February 29,
2020 |
|
March 2,
2019 |
|||||
Net sales
|
100.0
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
|
(7.2
|
)%
|
|
(2.6
|
)%
|
|
|
|
|
|
|
|
|
|
|
|||||
Cost of sales
|
68.3
|
|
|
65.9
|
|
|
64.0
|
|
|
(3.9
|
)
|
|
0.2
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Gross profit
|
31.7
|
|
|
34.1
|
|
|
36.0
|
|
|
(13.7
|
)
|
|
(7.6
|
)
|
|
|
|
|
|
|
|
|
|
|
|||||
Selling, general and administrative expenses
|
33.4
|
|
|
30.6
|
|
|
29.8
|
|
|
1.4
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Goodwill and other impairments
|
4.6
|
|
|
4.2
|
|
|
—
|
|
|
(0.1
|
)
|
|
100.0
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Operating (loss) profit
|
(6.3
|
)
|
|
(0.7
|
)
|
|
6.2
|
|
|
703.4
|
|
|
(111.4
|
)
|
|
|
|
|
|
|
|
|
|
|
|||||
Interest expense, net
|
0.6
|
|
|
0.6
|
|
|
0.5
|
|
|
(6.7
|
)
|
|
5.8
|
|
|
|
|
|
|
|
|
|
|
|
|||||
(Loss) earnings before provision for income taxes
|
(6.9
|
)
|
|
(1.3
|
)
|
|
5.6
|
|
|
388.4
|
|
|
(122.5
|
)
|
|
|
|
|
|
|
|
|
|
|
|||||
(Benefit) provision for income taxes
|
(1.4
|
)
|
|
(0.2
|
)
|
|
2.2
|
|
|
679.1
|
|
|
(107.2
|
)
|
|
|
|
|
|
|
|
|
|
|
|||||
Net (loss) earnings
|
(5.5
|
)
|
|
(1.1
|
)
|
|
3.4
|
|
|
347.3
|
|
|
(132.3
|
)
|
(in thousands)
|
|
Total
|
|
Less than 1 year
|
|
1-3 years
|
|
4-5 years
|
|
After 5
years
|
||||||||||
Senior unsecured notes
(1)
|
|
$
|
1,495,377
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,495,377
|
|
Interest on senior unsecured notes
(1)
|
|
1,402,518
|
|
|
72,304
|
|
|
144,608
|
|
|
139,071
|
|
|
1,046,535
|
|
|||||
Operating lease obligations
(2)
|
|
2,875,024
|
|
|
590,582
|
|
|
939,479
|
|
|
591,657
|
|
|
753,306
|
|
|||||
Purchase obligations
(3)
|
|
1,004,824
|
|
|
1,004,824
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Long-term sale/leaseback and finance lease obligations
(4)
|
|
301,419
|
|
|
10,470
|
|
|
20,841
|
|
|
21,226
|
|
|
248,882
|
|
|||||
Other long-term liabilities
(5)
|
|
149,459
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total Contractual Obligations
|
|
$
|
7,228,621
|
|
|
$
|
1,678,180
|
|
|
$
|
1,104,928
|
|
|
$
|
751,954
|
|
|
$
|
3,544,100
|
|
Consolidated Balance Sheets as of
February 29, 2020 and March 2, 2019
|
|
|
|
Consolidated Statements of Operations for the fiscal years ended
February 29, 2020, March 2, 2019, and March 3, 2018
|
|
|
|
Consolidated Statements of Comprehensive (Loss) Income for the fiscal years ended
February 29, 2020, March 2, 2019, and March 3, 2018
|
|
|
|
Consolidated Statements of Shareholders’ Equity for the fiscal years ended
February 29, 2020, March 2, 2019, and March 3, 2018
|
|
|
|
Consolidated Statements of Cash Flows for the fiscal years ended
February 29, 2020, March 2, 2019, and March 3, 2018
|
|
|
|
|
|
|
February 29,
2020 |
|
March 2,
2019 |
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
|
|
|
$
|
|
|
Short term investment securities
|
|
|
|
|
|
||
Merchandise inventories
|
|
|
|
|
|
||
Prepaid expenses and other current assets
|
|
|
|
|
|
||
Assets held-for-sale
|
|
|
|
|
|
||
|
|
|
|
||||
Total current assets
|
|
|
|
|
|
||
|
|
|
|
||||
Long term investment securities
|
|
|
|
|
|
||
Property and equipment, net
|
|
|
|
|
|
||
Operating lease assets
|
|
|
|
—
|
|
||
Goodwill
|
|
|
|
|
|
||
Other assets
|
|
|
|
|
|
||
|
|
|
|
||||
Total assets
|
$
|
|
|
|
$
|
|
|
|
|
|
|
||||
Liabilities and Shareholders' Equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
|
|
|
$
|
|
|
Accrued expenses and other current liabilities
|
|
|
|
|
|
||
Merchandise credit and gift card liabilities
|
|
|
|
|
|
||
Current operating lease liabilities
|
|
|
|
—
|
|
||
Liabilities related to assets held-for-sale
|
|
|
|
|
|
||
Current income taxes payable
|
|
|
|
|
|
||
|
|
|
|
||||
Total current liabilities
|
|
|
|
|
|
||
|
|
|
|
||||
Other liabilities
|
|
|
|
|
|
||
Operating lease liabilities
|
|
|
|
—
|
|
||
Income taxes payable
|
|
|
|
|
|
||
Long term debt
|
|
|
|
|
|
||
|
|
|
|
||||
Total liabilities
|
|
|
|
|
|
||
|
|
|
|
||||
Shareholders' equity:
|
|
|
|
||||
Preferred stock - $0.01 par value; authorized - 1,000 shares; no shares issued or outstanding
|
|
|
|
|
|
||
|
|
|
|
||||
Common stock - $0.01 par value; authorized - 900,000 shares; issued 343,683 and 342,582, respectively; outstanding 126,528 and 132,233 shares, respectively
|
|
|
|
|
|
||
Additional paid-in capital
|
|
|
|
|
|
||
Retained earnings
|
|
|
|
|
|
||
Treasury stock, at cost
|
(
|
)
|
|
(
|
)
|
||
Accumulated other comprehensive loss
|
(
|
)
|
|
(
|
)
|
||
|
|
|
|
||||
Total shareholders' equity
|
|
|
|
|
|
||
|
|
|
|
||||
Total liabilities and shareholders' equity
|
$
|
|
|
|
$
|
|
|
|
Twelve Months Ended
|
||||||||||
|
February 29, 2020
|
|
March 2, 2019
|
|
March 3, 2018
|
||||||
Net sales
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
||||||
Cost of sales
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
||||||
Gross profit
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
||||||
Selling, general and administrative expenses
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
||||||
Goodwill and other impairments
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
||||||
Operating (loss) profit
|
(
|
)
|
|
(
|
)
|
|
|
|
|||
|
|
|
|
|
|
||||||
Interest expense, net
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
||||||
(Loss) earnings before provision for income taxes
|
(
|
)
|
|
(
|
)
|
|
|
|
|||
|
|
|
|
|
|
||||||
(Benefit) provision for income taxes
|
(
|
)
|
|
(
|
)
|
|
|
|
|||
|
|
|
|
|
|
||||||
Net (loss) earnings
|
$
|
(
|
)
|
|
$
|
(
|
)
|
|
$
|
|
|
|
|
|
|
|
|
||||||
Net (loss) earnings per share - Basic
|
$
|
(
|
)
|
|
$
|
(
|
)
|
|
$
|
|
|
Net (loss) earnings per share - Diluted
|
$
|
(
|
)
|
|
$
|
(
|
)
|
|
$
|
|
|
|
|
|
|
|
|
||||||
Weighted average shares outstanding - Basic
|
|
|
|
|
|
|
|
|
|||
Weighted average shares outstanding - Diluted
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
||||||
Dividends declared per share
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
Twelve Months Ended
|
||||||||||
|
February 29, 2020
|
|
March 2, 2019
|
|
March 3, 2018
|
||||||
Net (loss) earnings
|
$
|
(
|
)
|
|
$
|
(
|
)
|
|
$
|
|
|
|
|
|
|
|
|
||||||
Other comprehensive (loss) income:
|
|
|
|
|
|
||||||
|
|
|
|
|
|
||||||
Change in temporary impairment of auction rate securities, net of taxes
|
|
|
|
|
|
|
|
|
|||
Pension adjustment, net of taxes
|
(
|
)
|
|
(
|
)
|
|
|
|
|||
Currency translation adjustment
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||
Reclassification due to the adoption of ASU 2018-02
|
|
|
|
|
|
|
(
|
)
|
|||
|
|
|
|
|
|
||||||
Other comprehensive (loss) income
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||
|
|
|
|
|
|
||||||
Comprehensive (loss) income
|
$
|
(
|
)
|
|
$
|
(
|
)
|
|
$
|
|
|
|
Common Stock
|
Additional Paid-
in Capital
|
Retained
Earnings
|
Treasury Stock
|
Accumulated Other
Comprehensive
Loss
|
Total
|
||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
||||||||||||||||||
Balance at February 25, 2017
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Net earnings
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Other comprehensive loss, net of tax
|
|
|
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Dividend declared
|
|
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Shares sold under employee stock option plans, net of taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Issuance of restricted shares, net
|
|
|
|
|
(
|
)
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Payment and vesting of performance stock units
|
|
|
|
|
(
|
)
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Stock-based compensation expense, net
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Director fees paid in stock
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Repurchase of common stock, including fees
|
|
|
|
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||||
Balance at March 3, 2018
|
|
|
|
|
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|
||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Net loss
|
|
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Other comprehensive loss, net of tax
|
|
|
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Effect of Adoption of ASU 2014-09
|
|
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Dividend declared
|
|
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Shares sold under employee stock option plans, net of taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Issuance of restricted shares, net
|
|
|
|
|
(
|
)
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Payment and vesting of performance stock units
|
|
|
|
|
(
|
)
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Stock-based compensation expense, net
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Director fees paid in stock
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Repurchase of common stock, including fees
|
|
|
|
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||||
Balance at March 2, 2019
|
|
|
|
|
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|
||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Net loss
|
|
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Other comprehensive loss, net of tax
|
|
|
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Effect of Adoption of ASU 2016-02
|
|
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Dividend declared
|
|
|
|
(
|
)
|
|
|
|
(
|
)
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Shares sold under employee stock option plans, net of taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Issuance of restricted shares, net
|
|
|
|
|
(
|
)
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Payment and vesting of performance stock units
|
|
|
|
|
(
|
)
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Stock-based compensation expense, net
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Director fees paid in stock
|
|
|
—
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||
Repurchase of common stock, including fees
|
|
|
|
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||||
Balance at February 29, 2020
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|
|
Twelve Months Ended
|
||||||||||
|
February 29, 2020
|
|
March 2, 2019
|
|
March 3, 2018
|
||||||
Cash Flows from Operating Activities:
|
|
|
|
|
|
|
|
|
|||
Net (loss) earnings
|
$
|
(
|
)
|
|
$
|
(
|
)
|
|
$
|
|
|
Adjustments to reconcile net (loss) earnings to net cash provided by operating activities:
|
|
|
|
|
|
||||||
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|||
Loss on sale leaseback transaction
|
|
|
|
—
|
|
|
—
|
|
|||
Gain on sale of building
|
|
|
|
(
|
)
|
|
|
|
|||
Gain on debt extinguishment
|
|
|
|
(
|
)
|
|
|
|
|||
Goodwill and other impairments
|
|
|
|
|
|
|
|
|
|||
Stock-based compensation
|
|
|
|
|
|
|
|
|
|||
Deferred income taxes
|
(
|
)
|
|
(
|
)
|
|
|
|
|||
Other
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||
Decrease (increase) in assets, net of effect of acquisitions:
|
|
|
|
|
|
||||||
Merchandise inventories
|
|
|
|
|
|
|
|
|
|||
Trading investment securities
|
|
|
|
|
|
|
(
|
)
|
|||
Other current assets
|
(
|
)
|
|
|
|
|
(
|
)
|
|||
Other assets
|
|
|
|
|
|
|
(
|
)
|
|||
(Decrease) increase in liabilities, net of effect of acquisitions:
|
|
|
|
|
|
||||||
Accounts payable
|
(
|
)
|
|
(
|
)
|
|
|
|
|||
Accrued expenses and other current liabilities
|
|
|
|
(
|
)
|
|
|
|
|||
Merchandise credit and gift card liabilities
|
|
|
|
|
|
|
|
|
|||
Income taxes payable
|
(
|
)
|
|
|
|
|
(
|
)
|
|||
Operating lease assets and liabilities, net
|
(
|
)
|
|
—
|
|
|
—
|
|
|||
Other liabilities
|
|
|
|
(
|
)
|
|
(
|
)
|
|||
|
|
|
|
|
|
||||||
Net cash provided by operating activities
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
||||||
Cash Flows from Investing Activities:
|
|
|
|
|
|
||||||
|
|
|
|
|
|
||||||
Purchase of held-to-maturity investment securities
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||
Redemption of held-to-maturity investment securities
|
|
|
|
|
|
|
|
|
|||
Capital expenditures
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||
Proceeds from sale-leaseback transaction
|
|
|
|
—
|
|
|
—
|
|
|||
Proceeds from sale of a building
|
|
|
|
|
|
|
|
|
|||
Payment for acquisitions, net of cash acquired
|
|
|
|
|
|
|
(
|
)
|
|||
|
|
|
|
|
|
||||||
Net cash provided by (used in) investing activities
|
|
|
|
(
|
)
|
|
(
|
)
|
|||
|
|
|
|
|
|
||||||
Cash Flows from Financing Activities:
|
|
|
|
|
|
||||||
|
|
|
|
|
|
||||||
Payment of dividends
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||
Repurchase of common stock, including fees
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||
Payment of senior notes
|
|
|
|
(
|
)
|
|
|
|
|||
Proceeds from exercise of stock options
|
|
|
|
|
|
|
|
|
|||
Payment of other liabilities
|
|
|
|
|
|
|
(
|
)
|
|||
|
|
|
|
|
|
||||||
Net cash used in financing activities
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||
|
|
|
|
|
|
||||||
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|||
|
|
|
|
|
|
||||||
Net increase (decrease) in cash, cash equivalents and restricted cash, including cash balances classified as assets held-for-sale
|
|
|
|
|
|
|
(
|
)
|
|||
Less: Cash balances classified as assets held-for sale
|
(
|
)
|
|
|
|
|
|
|
|||
Net increase (decrease) in cash, cash equivalents and restricted cash
|
|
|
|
|
|
|
(
|
)
|
|||
|
|
|
|
|
|
||||||
Cash, cash equivalents and restricted cash:
|
|
|
|
|
|
||||||
|
|
|
|
|
|
||||||
Beginning of period
|
|
|
|
|
|
|
|
|
|||
End of period
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
1.
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS
|
A.
|
Nature of Operations
|
B.
|
Fiscal Year
|
C.
|
Principles of Consolidation
|
D.
|
Use of Estimates
|
E.
|
Recent Accounting Pronouncements
|
F.
|
Cash and Cash Equivalents
|
G.
|
Investment Securities
|
H.
|
Inventory Valuation
|
I.
|
Property and Equipment
|
J.
|
Impairment of Long-Lived Assets
|
K.
|
Goodwill and Other Indefinite Lived Intangible Assets
|
L.
|
Self-Insurance
|
M.
|
Shareholders’ Equity
|
N.
|
Fair Value of Financial Instruments
|
O.
|
Leases
|
P.
|
Assets Held for Sale
|
Q.
|
Revenue Recognition
|
R.
|
Cost of Sales
|
S.
|
Vendor Allowances
|
T.
|
Store Opening, Expansion, Relocation and Closing Costs
|
U.
|
Advertising Costs
|
V.
|
Stock-Based Compensation
|
W.
|
Income Taxes
|
X.
|
Earnings per Share
|
5.
|
INVESTMENT SECURITIES
|
(in millions)
|
|
February 29, 2020
|
|
March 2, 2019
|
||||
Available-for-sale securities:
|
|
|
|
|
||||
Long term
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
||||
Held-to-maturity securities:
|
|
|
|
|
||||
Short term
|
|
|
|
|
|
|
||
Total investment securities
|
|
$
|
|
|
|
$
|
|
|
(in thousands)
|
February 29, 2020
|
|
March 2, 2019
|
||||
Land and buildings
|
$
|
|
|
|
$
|
|
|
Furniture, fixtures and equipment
|
|
|
|
|
|
||
Leasehold improvements
|
|
|
|
|
|
||
Computer equipment and software
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
||||
Less: Accumulated depreciation
|
(
|
)
|
|
(
|
)
|
||
Property and equipment, net
|
$
|
|
|
|
$
|
|
|
8.
|
PROVISION FOR INCOME TAXES
|
|
FISCAL YEAR ENDED
|
||||||||||
(in thousands)
|
February 29, 2020
|
|
March 2, 2019
|
|
March 3, 2018
|
||||||
Current:
|
|
|
|
|
|
|
|
|
|||
Federal
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
State and local
|
(
|
)
|
|
|
|
|
|
|
|||
|
(
|
)
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
||||||
Deferred:
|
|
|
|
|
|
||||||
Federal
|
(
|
)
|
|
(
|
)
|
|
|
|
|||
State and local
|
(
|
)
|
|
(
|
)
|
|
|
|
|||
|
(
|
)
|
|
(
|
)
|
|
|
|
|||
|
$
|
(
|
)
|
|
$
|
(
|
)
|
|
$
|
|
|
(in thousands)
|
February 29, 2020
|
|
March 2, 2019
|
||||
Deferred tax assets:
|
|
|
|
|
|
||
Inventories
|
$
|
|
|
|
$
|
|
|
Deferred rent and other rent credits
|
|
|
|
|
|
||
Insurance
|
|
|
|
|
|
||
Stock-based compensation
|
|
|
|
|
|
||
Nonqualified deferred compensation plan
|
|
|
|
|
|
||
Merchandise credits and gift card liabilities
|
|
|
|
|
|
||
Accrued expenses
|
|
|
|
|
|
||
Obligations on distribution facilities
|
|
|
|
|
|
||
Goodwill
|
|
|
|
|
|
||
Carryforwards and other tax credits
|
|
|
|
|
|
||
Other
|
|
|
|
|
|
||
|
|
|
|
||||
Deferred tax liabilities:
|
|
|
|
||||
Depreciation
|
(
|
)
|
|
(
|
)
|
||
Goodwill
|
|
|
|
(
|
)
|
||
Intangibles
|
(
|
)
|
|
(
|
)
|
||
Prepaid expenses
|
(
|
)
|
|
(
|
)
|
||
Other
|
(
|
)
|
|
(
|
)
|
||
|
$
|
|
|
|
$
|
|
|
(in thousands)
|
February 29, 2020
|
|
March 2, 2019
|
||||
Balance at beginning of year
|
$
|
|
|
|
$
|
|
|
|
|
|
|
||||
Increase related to current year positions
|
|
|
|
|
|
||
Increase related to prior year positions
|
|
|
|
|
|
||
Decrease related to prior year positions
|
(
|
)
|
|
(
|
)
|
||
Settlements
|
(
|
)
|
|
(
|
)
|
||
Lapse of statute of limitations
|
(
|
)
|
|
(
|
)
|
||
|
|
|
|
||||
Balance at end of year
|
$
|
|
|
|
$
|
|
|
|
|
FISCAL YEAR ENDED
|
|||||
|
|
February 29, 2020
|
March 2, 2019
|
March 3, 2018
|
|||
|
|
|
|
|
|||
Federal statutory rate
|
|
|
%
|
|
%
|
|
%
|
State income tax rate, net of federal impact
|
|
|
|
(
|
)
|
|
|
Uncertain tax positions
|
|
|
|
|
|
|
|
Impact of the Tax Act
|
|
|
|
|
|
|
|
Goodwill non-deductible impairment charges
|
|
(
|
)
|
(
|
)
|
|
|
Tax deficiencies related to stock-based compensation
|
|
(
|
)
|
(
|
)
|
|
|
Tax credits
|
|
|
|
|
|
(
|
)
|
Other
|
|
|
|
|
|
(
|
)
|
|
|
|
%
|
|
%
|
|
%
|
9.
|
TRANSACTIONS AND BALANCES WITH RELATED PARTIES
|
10.
|
LEASES
|
(in thousands)
|
Statement of Operations Location
|
Fiscal year ended February 29, 2020
|
||
Operating lease cost
|
Cost of sales and SG&A
|
$
|
|
|
Finance lease cost:
|
|
|
||
Depreciation of property
|
SG&A
|
|
|
|
Interest on lease liabilities
|
Interest expense, net
|
|
|
|
Variable lease cost
|
Cost of sales and SG&A
|
|
|
|
Sublease income
|
SG&A
|
(
|
)
|
|
Total lease cost
|
|
$
|
|
|
(in thousands)
|
Consolidated Balance Sheet Location
|
February 29, 2020
|
||
Assets
|
|
|
||
Operating leases
|
Operating lease assets
|
$
|
|
|
Finance leases
|
Property and equipment, net
|
|
|
|
Total Lease assets
|
|
$
|
|
|
|
|
|
||
Liabilities
|
|
|
||
Current:
|
|
|
||
Operating leases
|
Current operating lease liabilities
|
$
|
|
|
Finance leases
|
Accrued expenses and other current liabilities
|
|
|
|
Noncurrent:
|
|
|
||
Operating leases
|
Operating lease liabilities
|
|
|
|
Finance leases
|
Other liabilities
|
|
|
|
Total lease liabilities
|
|
$
|
|
|
|
Operating Leases
|
|
Finance Leases
|
||||
Fiscal Year:
|
|
|
|
||||
2020
|
$
|
|
|
|
$
|
|
|
2021
|
|
|
|
|
|
||
2022
|
|
|
|
|
|
||
2023
|
|
|
|
|
|
||
2024
|
|
|
|
|
|
||
Thereafter
|
|
|
|
|
|
||
Total lease payments
|
$
|
|
|
|
$
|
|
|
Less imputed interest
|
(
|
)
|
|
(
|
)
|
||
Present value of lease liabilities
|
$
|
|
|
|
$
|
|
|
|
|
February 29, 2020
|
|
Weighted-average remaining lease term (in years)
|
|
|
|
Operating leases
|
|
|
|
Finance leases
|
|
|
|
Weighted-average discount rate
|
|
|
|
Operating leases
|
|
|
%
|
Finance leases
|
|
|
%
|
(in thousands)
|
|
Fiscal year ended February 29, 2020
|
||
Cash paid for amounts included in the measurement of lease liabilities
|
|
|
||
Operating cash flows from operating leases
|
|
$
|
|
|
Operating cash flows from finance leases
|
|
|
|
|
Operating lease assets obtained in exchange for new operating lease liabilities
|
|
|
|
(in thousands)
|
Operating Leases
|
||
Fiscal Year:
|
|
||
2019
|
$
|
|
|
2020
|
|
|
|
2021
|
|
|
|
2022
|
|
|
|
2023
|
|
|
|
Thereafter
|
|
|
|
Total future minimum lease payments
|
$
|
|
|
11.
|
EMPLOYEE BENEFIT PLANS
|
12.
|
COMMITMENTS AND CONTINGENCIES
|
13.
|
SUPPLEMENTAL CASH FLOW INFORMATION
|
14.
|
STOCK-BASED COMPENSATION
|
|
|
FISCAL YEAR ENDED
|
|||||||
Black-Scholes Valuation Assumptions (1)
|
|
February 29, 2020
|
|
March 2, 2019
|
|
March 3, 2018
|
|||
Weighted Average Expected Life (in years) (2)
|
|
|
|
|
|
|
|
|
|
Weighted Average Expected Volatility (3)
|
|
|
%
|
|
|
%
|
|
|
%
|
Weighted Average Risk Free Interest Rates (4)
|
|
|
%
|
|
|
%
|
|
|
%
|
Expected Dividend Yield (5)
|
|
|
%
|
|
|
%
|
|
|
%
|
(Shares in thousands)
|
|
Number of Stock Options
|
|
Weighted Average Exercise Price
|
|||
Options outstanding, beginning of period
|
|
|
|
|
$
|
|
|
Granted
|
|
|
|
|
|
|
|
Exercised
|
|
(
|
)
|
|
|
|
|
Forfeited or expired
|
|
(
|
)
|
|
|
|
|
Options outstanding, end of period
|
|
|
|
|
|
|
|
Options exercisable, end of period
|
|
|
|
|
$
|
|
|
(Shares in thousands)
|
|
Number of Restricted Shares
|
|
Weighted Average Grant-Date Fair
Value
|
|||
Unvested restricted stock, beginning of period
|
|
|
|
|
$
|
|
|
Granted
|
|
|
|
|
|
|
|
Vested
|
|
(
|
)
|
|
|
|
|
Forfeited
|
|
(
|
)
|
|
|
|
|
Unvested restricted stock, end of period
|
|
|
|
|
$
|
|
|
(Shares in thousands)
|
|
Number of Performance Stock Units
|
|
Weighted Average Grant-Date Fair
Value
|
|||
Unvested performance stock units, beginning of period
|
|
|
|
|
$
|
|
|
Granted
|
|
|
|
|
|
|
|
Vested
|
|
(
|
)
|
|
|
|
|
Forfeited
|
|
(
|
)
|
|
|
|
|
Unvested performance stock units, end of period
|
|
|
|
|
$
|
|
|
•
|
Time-vesting restricted stock units ("RSUs") consisting of the following:
|
◦
|
|
◦
|
|
•
|
|
15.
|
SUMMARY OF QUARTERLY RESULTS (UNAUDITED)
|
|
FISCAL 2019 QUARTER ENDED
|
FISCAL 2018 QUARTER ENDED
|
||||||||||||||||||||||
(in thousands, except per share data)
|
June 1, 2019
|
August 31, 2019
|
November 30, 2019
|
February 29, 2020
|
June 2, 2018
|
September 1, 2018
|
December 1, 2018
|
March 2, 2019
|
||||||||||||||||
Net sales
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
Gross profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating profit (loss)
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|
|
|
|
|
(
|
)
|
||||||||
Earnings (loss) before provision for income taxes
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|
|
|
|
|
(
|
)
|
||||||||
Provision (benefit) for income taxes
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|
|
|
|
|
|
(
|
)
|
||||||||
Net earnings (loss)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
(
|
)
|
EPS-Basic (1)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
(
|
)
|
EPS-Diluted (1)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
(
|
)
|
Dividends declared per share
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
16.
|
ASSETS HELD FOR SALE
|
(a)
|
Directors of the Company
|
(b)
|
Executive Officers of the Company
|
(c)
|
Information with respect to compliance with Section 16(a) of the Securities Exchange Act of 1934 is set forth under the section captioned “Delinquent Section 16(a) Reports” in the Proxy Statement and is incorporated herein by reference, to the extent responsive disclosure is required.
|
(d)
|
Information on our audit committee and the audit committee financial expert is set forth under the section captioned “Audit Committee” in the Proxy Statement and is incorporated herein by reference.
|
(e)
|
The Company has adopted a code of ethics entitled “Policy Of Ethical Standards For Business Conduct” that applies to all of its employees, including Executive Officers, and the Board of Directors, the complete text of which is available through the Investor Relations section of the Company’s website, www.bedbathandbeyond.com. Amendments to, and waivers granted under, the Policy Of Ethical Standards for Business Conduct, if any, will be posted to the Company’s website as well.
|
Plan Category
|
Number of securities to be issued upon exercise
of outstanding options, warrants and rights
(a)
|
Weighted-average exercise price of
outstanding options, warrants and rights
(b)
|
Number of securities remaining available for future
issuance under equity compensation plans (excluding
securities reflected in column (a))
(c)
|
||||||
Equity compensation plans approved by shareholders (1)
|
2,539,154
|
|
(2)
|
$
|
40.19
|
|
(3)
|
14,348,220
|
|
Equity compensation plans not approved by shareholders
|
273,735
|
|
|
—
|
|
|
20
|
|
|
Total (4)
|
2,812,889
|
|
(2)
|
$
|
40.19
|
|
(3)
|
14,348,240
|
|
(1)
|
These plans consist of the Company’s 2004 Incentive Compensation Plan and the 2012 Incentive Compensation Plan, which amended and restated the 2004 Incentive Compensation Plan.
|
(2)
|
This amount includes 1,716,521 shares that may be issued upon the vesting of performance stock units granted under the 2012 Incentive Compensation Plan, which represents the estimated maximum number of shares that may be issued upon the vesting of the performance stock units. This amount also includes 822,633 of stock options outstanding.
|
(3)
|
The weighted-average exercise price solely takes into account outstanding stock options as other outstanding awards under the 2004 Incentive Compensation Plan and the 2012 Incentive Compensation Plan do not have an exercise price.
|
(4)
|
Any shares of common stock that are subject to awards of options or stock appreciation rights under the 2012 Incentive Compensation Plan shall be counted against the aggregate number of shares of common stock that may be issued as one share for every share issued. Any shares of common stock that are subject to awards other than options or stock appreciation rights, including restricted stock awards and performance stock units, shall be counted against this limit as 2.20 shares for every share granted.
|
Exhibit
No.
|
Exhibit
|
3.1***
|
Restated Certificate of Incorporation
|
3.2
|
|
3.3
|
|
3.4
|
|
3.5
|
|
3.6
|
|
3.7
|
|
3.8
|
|
4.1
|
|
4.2
|
|
4.3
|
|
4.4
|
|
4.5
|
|
4.6**
|
|
10.1*
|
|
10.2*
|
|
10.3*
|
10.4*
|
|
10.5*
|
|
10.6*
|
|
10.7*
|
|
10.8*
|
|
10.9*
|
|
10.10*
|
|
10.11*
|
|
10.12*
|
|
10.13*
|
|
10.14*
|
|
10.15*
|
|
10.16*
|
|
10.17*
|
|
10.18*
|
|
10.19*
|
|
10.20*
|
|
10.21*
|
|
10.22*
|
|
10.23*
|
|
10.24*
|
|
10.25*
|
10.26*
|
|
10.27*
|
|
10.28*
|
|
10.29*
|
|
10.30*
|
|
10.31*
|
|
10.32*
|
|
10.33*
|
|
10.34*
|
|
10.35*
|
|
10.36*
|
|
10.37*
|
|
10.38*
|
|
10.39*
|
|
10.40*
|
|
10.41*
|
|
10.42*
|
|
10.43*
|
|
10.44*
|
|
10.45*
|
|
10.46*
|
|
10.47*
|
10.48
|
|
21**
|
|
23**
|
|
31.1**
|
|
31.2**
|
|
32**
|
|
101.INS
|
Inline XBRL Instance Document
|
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document
|
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
104
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
|
*
|
This is a management contract or compensatory plan or arrangement.
|
**
|
Filed herewith.
|
***
|
This Exhibit was originally filed in paper format. Accordingly, a hyperlink has not been provided.
|
Signature
|
|
Capacity
|
|
Date
|
|
|
|
|
|
/s/ Mark J. Tritton
|
|
President and Chief Executive Officer
|
|
April 29, 2020
|
Mark J. Tritton
|
|
and Director
|
|
|
|
|
|
|
|
/s/ Robyn M. D'Elia
|
|
Chief Financial Officer and Treasurer
|
|
April 29, 2020
|
Robyn M. D'Elia
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Stephanie Bell-Rose
|
|
Director
|
|
April 29, 2020
|
Stephanie Bell-Rose
|
|
|
|
|
|
|
|
|
|
/s/ Harriet Edelman
|
|
Director
|
|
April 29, 2020
|
Harriet Edelman
|
|
|
|
|
|
|
|
|
|
/s/ John E. Fleming
|
|
Director
|
|
April 29, 2020
|
John E. Fleming
|
|
|
|
|
|
|
|
|
|
/s/ Patrick R. Gaston
|
|
Director
|
|
April 29, 2020
|
Patrick R. Gaston
|
|
|
|
|
|
|
|
|
|
/s/ Sue E. Gove
|
|
Director
|
|
April 29, 2020
|
Sue E. Gove
|
|
|
|
|
|
|
|
|
|
/s/ Jeffrey A. Kirwan
|
|
Director
|
|
April 29, 2020
|
Jeffrey A. Kirwan
|
|
|
|
|
|
|
|
|
|
/s/ Johnathan B. (JB) Osborne
|
|
Director
|
|
April 29, 2020
|
Johnathan B. (JB) Osborne
|
|
|
|
|
|
|
|
|
|
s/ Harsha Ramalingam
|
|
Director
|
|
April 29, 2020
|
Harsha Ramalingam
|
|
|
|
|
|
|
|
|
|
/s/ Virginia P. Ruesterholz
|
|
Director
|
|
April 29, 2020
|
Virginia P. Ruesterholz
|
|
|
|
|
|
|
|
|
|
/s/ Joshua E. Schechter
|
|
Director
|
|
April 29, 2020
|
Joshua E. Schechter
|
|
|
|
|
|
|
|
|
|
/s/ Andrea Weiss
|
|
Director
|
|
April 29, 2020
|
Andrea Weiss
|
|
|
|
|
|
|
|
|
|
/s/ Mary A .Winston
|
|
Director
|
|
April 29, 2020
|
Mary A. Winston
|
|
|
|
|
|
|
|
|
|
/s/ Ann Yerger
|
|
Director
|
|
April 29, 2020
|
Ann Yerger
|
|
|
|
|
Column A
|
|
Column B
|
|
Column C
|
|
Column C
|
|
Column D
|
|
Column E
|
|||||||||||
Description
|
|
Balance at Beginning of
Period
|
|
Additions Charged to
Income
|
|
Additions Charged to Other
Accounts
|
|
Adjustments and/or Deductions
|
|
Balance at End of Period
|
|||||||||||
Sales Returns and Allowance
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Year Ended:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
February 29, 2020
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
$
|
|
|
|
$
|
|
|
March 2, 2019
|
|
|
|
|
|
|
|
|
|
(1)
|
|
|
|
|
|
|
|||||
March 3, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|---|---|---|
Dr. Vandebroek has served as founder and owner of Strategic Vision Ventures, LLC, a technology consulting firm, since 2021. Previously, Dr. Vandebroek was the inaugural visiting scholar at the Massachusetts Institute of Technology School of Engineering for the 2019-2020 academic year; Vice President, Emerging Technology Partnerships for IBM from 2018 to 2019; and Chief Operating Officer - IBM Research from 2017 to 2018. Prior to joining IBM, she was an executive with Xerox Corporation, where her roles included serving as Chief Technology Officer and Corporate Vice President of Xerox Corporation, President of the Xerox Innovation Group, and Chief Engineer. She was also responsible for overseeing Xerox’s global research centers, including the Palo Alto Research Center, or PARC Inc. Dr. Vandebroek currently serves on the boards of IDEXX Laboratories, Inc. and Wolters Kluwer N. V., both of which are publicly traded, as well as Inari Agriculture, Inc., a privately held biotechnology company, and formerly served on the board of Analogic Corporation. In 2021, Dr. Vandebroek was appointed an honorary Professor at KU Leuven, Belgium. Dr. Vandebroek is the Chair of the Advisory Committee of the Flanders AI Research Program and a Fellow of the Institute of Electrical & Electronics Engineers. Dr. Vandebroek holds a bachelor’s degree and a master’s degree in electro-mechanical engineering from KU Leuven, Leuven, Belgium, and a doctoral degree in electrical engineering from Cornell University. | |||
Mr. Chapin retired from Bank of America Merrill Lynch in 2016 as Executive Vice Chairman of Global Corporate & Investment Banking, after more than thirty years in investment banking. As Executive Vice Chairman from 2010 to 2016 he was responsible for managing relationships with some of the firm’s largest clients. Mr. Chapin has worked on a broad range of financings and strategic advisory assignments totaling more than $500 billion and has been named Investment Banker of the Year by Investment Dealers’ Digest . Mr. Chapin was named Vice Chairman of Merrill Lynch & Co., Inc. in 2003 and was a member of the firm’s executive Operating Committee. Mr. Chapin served in a number of other senior leadership positions while at Bank of America Merrill Lynch, including having responsibility for the Global Investment Banking division and managing many of the firm’s global corporate relationships. Mr. Chapin has served since 2019 as a Senior Advisor to Rockefeller Capital Management, a leading independent, privately owned financial services firm. He is also a member of the board of directors of O-I Glass, Inc. and PHINIA, Inc., both of which are publicly traded, and until 2023 was a director of CIRCOR International, Inc. Additionally, he serves as a trustee emeritus of Lafayette College and as a director emeritus of New York’s Roundabout Theatre Company. Mr. Chapin holds a Bachelor of Arts degree from Lafayette College and a Master of Business Administration degree from The Wharton School at the University of Pennsylvania. | |||
Dr. Singh was elected President and Chief Executive Officer of Revvity effective December 30, 2019, and appointed to our board of directors in 2019. Previously, Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined Revvity as the President of our Diagnostics business in 2014. He was elected Senior Vice President in 2016 and Executive Vice President in 2018. Prior to joining Revvity, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently at Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region. | |||
Dr. Barrett joined Atlas Venture, an early-stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group, where he has been involved in the creation of several therapeutic and drug discovery platform companies. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics which in 2001 announced the first successful sequencing of the human genome. Prior to that, Dr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development, where he operated several businesses and helped to greatly expand its life sciences portfolio through a series of licensing agreements, partnerships and acquisitions. He currently serves as the Chairman of Synlogic, Inc., which is publicly traded, and is a board member of privately held Obsidian Therapeutics, Inc. Dr. Barrett is also an executive fellow at the Harvard Business School and is the chair of the key advisory board of the Blavatnik Fellowship program. Dr. Barrett previously served on the board of Larimar Therapeutics, Inc., a publicly traded company, until 2023. In addition, Dr. Barrett is a board member of Nucleate, a student run non-profit organization representing the global community of bio-innovators. Dr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his doctoral degree in analytical chemistry from Northeastern University. | |||
Ms. Witz has served as the President of PWH Advisors, a consultancy firm advising healthcare and investment companies, since founding the firm in 2016. Previously, Ms. Witz served as a Member of the Executive Committee for Sanofi, S. A., most recently as Executive Vice President, Global Diabetes & Cardiovascular, and previously as Executive Vice President, Global Pharma and Consumer Healthcare divisions. Before joining Sanofi, Ms. Witz served as President and Chief Executive Officer of GE’s pharmaceutical diagnostics, a $2 billion integrated pharmaceutical business that encompassed research and development through commercialization. Previously Ms. Witz served with GE Healthcare, where she held positions of increasing responsibility in Europe and the United States. Before joining GE Healthcare, Ms. Witz was previously employed with Becton Dickinson Pharmaceutical Systems. Ms. Witz currently serves on the boards of publicly traded companies Fresenius Medical Care AG and Regulus Therapeutics, Inc., as well as several privately held companies. Ms. Witz formerly served on the boards of publicly traded Horizon Therapeutics plc until 2023, Savencia SA until 2018, and Tesaro, Inc. until 2019. Ms. Witz received her Master of Business Administration degree from INSEAD, Fontainebleau, France and her Master of Science degree in biochemistry from the Institut National des Sciences Appliquées, Lyon, France. She was also a doctoral student in molecular biology at the Centre National de la Recherche Scientifique, Strasbourg, France. | |||
MICHELLE MCMURRY-HEATH, MD, PhD : Age 55; Principal Occupation: Founder and Chief Executive Officer, BioTechquity Clinical. Director of Revvity since 2022. Member of the compensation and benefits committee. | |||
MICHEL VOUNATSOS : Age 63; Principal Occupation: Former Chief Executive Officer of Biogen Inc. Director of Revvity since 2020. Chair of the nominating and corporate governance committee and member of the audit committee. | |||
Mr. Klobuchar joined Eikon Therapeutics in 2024, and oversees the company’s corporate infrastructure, including global supply chain management and product manufacturing. Mr. Klobuchar is a member of Eikon’s Executive Committee and manages key executives across a variety of functional areas and business operations. Prior to joining Eikon, Mr. Klobuchar had been associated with Merck & Co., Inc., a premier research-intensive global biopharmaceutical company, for over 25 years, most recently serving from 2021 to 2024 as Executive Vice President and Chief Strategy Officer, and from 2019 to 2021 as Senior Vice President, CFO and Head of Portfolio and Alliance Management for Merck Research Laboratories. Prior to that, Mr. Klobuchar held a variety of positions of increasing responsibility in Merck’s research, manufacturing, commercial planning, finance and strategy organizations, including leading key elements related to the integration of Merck Research Laboratories with Schering-Plough R&D following the merger of the two companies. Mr. Klobuchar received his Master of Business Administration degree from Villanova University, a Master of Science degree in chemical engineering from Rutgers University and a Bachelor of Science degree from Purdue University. | |||
FRANK WITNEY, PhD : Age 71; Principal Occupation: Former Chief Executive Officer, Affymetrix, Inc., a leading provider of microarray technology; Director of Revvity since 2016. Member of the compensation and benefits and nominating and corporate governance committees. | |||
Mr. Michas was named Non-Executive Chair of the board as of December 30, 2019. He brings to our board, and to the position of Non-Executive Chair, many years of private equity experience across a wide range of industries, and a successful record of managing investments in public companies. Mr. Michas also brings extensive transactional expertise, including mergers and acquisitions, IPOs, debt and equity offerings, and bank financing. This expertise allows Mr. Michas to provide our board with valuable insight on trends in global debt and equity markets, and the impact of such trends on the capital structure of the Company. We also benefit from the corporate governance knowledge developed by Mr. Michas in his board roles with other public companies, including his service as a board chair, a lead director, and a member of the compensation, governance, audit, finance and executive committees of such companies. Mr. Michas’ thorough knowledge of the Company and his current and past service on the boards of other public companies make him uniquely qualified to serve as our Non-Executive Chair. |
Name and Principal Position |
Year |
Salary
($) |
Bonus
($) |
Stock
Awards ($) |
Option
Awards ($) |
Non-Equity
Incentive Plan Compensation ($) |
All Other
Compensation ($) |
Total ($) | ||||||||||||||||||||||||||||||||
Prahlad R. Singh Chief Executive Officer |
2024 | $ | 1,100,000 | — | $ | 4,125,038 | $ | 4,116,298 | $ | 2,530,440 | $ | 54,839 | $ | 11,926,615 | ||||||||||||||||||||||||||
2023 | $ | 1,086,539 | — | $ | 5,775,022 | $ | 1,921,023 | $ | 315,563 | $ | 32,477 | $ | 9,130,624 | |||||||||||||||||||||||||||
2022 | $ | 1,050,000 | — | $ | 5,512,467 | $ | 1,836,460 | $ | 2,152,763 | $ | 25,309 | $ | 10,576,998 | |||||||||||||||||||||||||||
Maxwell Krakowiak Senior Vice President and Chief Financial Officer
|
2024 | $ | 507,692 | — | $ | 1,050,013 | $ | 1,047,775 | $ | 615,038 | $ | 25,168 | $ | 3,245,686 | ||||||||||||||||||||||||||
2023 | $ | 500,000 | — | $ | 1,468,779 | $ | 654,938 | $ | 111,563 | $ | 19,548 | $ | 2,754,828 | |||||||||||||||||||||||||||
2022 | $ | 365,124 | $ | 50,000 | $ | 324,899 | $ | 324,955 | $ | 383,210 | $ | 16,250 | $ | 1,464,439 | ||||||||||||||||||||||||||
Joel S. Goldberg Senior Vice President, Administration, General Counsel and Secretary
|
2024 | $ | 550,000 | — | $ | 1,031,208 | $ | 1,029,084 | $ | 732,188 | $ | 39,086 | $ | 3,381,566 | ||||||||||||||||||||||||||
2023 | $ | 547,308 | — | $ | 1,443,756 | $ | 480,244 | $ | 122,719 | $ | 50,715 | $ | 2,644,742 | |||||||||||||||||||||||||||
2022 | $ | 538,115 | — | $ | 1,214,971 | $ | 404,768 | $ | 703,688 | $ | 44,015 | $ | 2,905,558 | |||||||||||||||||||||||||||
Miriame Victor Senior Vice President and Chief Commercial Officer
|
2024 | $ | 467,692 | — | $ | 727,508 | $ | 725,981 | $ | 530,299 | $ | 26,166 | $ | 2,477,646 | ||||||||||||||||||||||||||
2023 | $ | 447,077 | — | $ | 862,557 | $ | 286,903 | $ | 83,870 | $ | 24,450 | $ | 1,704,856 | |||||||||||||||||||||||||||
Tajinder S. Vohra Senior Vice President Global Operations
|
2024 | $ | 475,000 | — | $ | 653,115 | $ | 651,738 | $ | 504,189 | $ | 25,311 | $ | 2,309,353 | ||||||||||||||||||||||||||
2023 | $ | 470,962 | — | $ | 890,613 | $ | 296,287 | $ | 79,943 | $ | 23,170 | $ | 1,760,975 | |||||||||||||||||||||||||||
2022 | $ | 451,923 | — | $ | 689,905 | $ | 229,892 | $ | 452,695 | $ | 22,623 | $ | 1,847,038 |
No Customers Found
Suppliers
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|---|---|---|
Singh Prahlad R. | - | 90,195 | 37,163 |
Singh Prahlad R. | - | 83,016 | 25,088 |
MICHAS ALEXIS P | - | 58,203 | 500 |
Goldberg Joel S | - | 33,400 | 63,709 |
Goldberg Joel S | - | 27,319 | 63,709 |
Vohra Tajinder S | - | 22,625 | 0 |
Witney Frank | - | 18,662 | 0 |
Witz Pascale | - | 13,705 | 0 |
Tereau Daniel R | - | 11,611 | 0 |
Krakowiak Maxwell | - | 7,202 | 0 |
Victor Miriame | - | 6,960 | 0 |
Gonzales Anita | - | 4,522 | 0 |
Okun Andrew | - | 4,356 | 8 |
Gonzales Anita | - | 3,859 | 0 |
McMurry-Heath Michelle | - | 3,021 | 0 |
Vandebroek Sophie V. | - | 481 | 0 |